Rejected Merck to present glucosamine data for peer review
date:Aug 18, 2012
n joint cartilage. The research we have conducted includes 61 references and is based on extrapolated data obtained from osteoarthritic patients as well as healthy people.

We will continue to discuss with EFSA to make claims viable for consumers. In addition to this, we plan on publishing a summary of the beneficial impact of glucosamine in a scientific journal.

The German pharma and did not expand on the journal or the timing of publication.

Patrick Coppens, the secretary general of the Euro
3/5 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/19 21:56